Regenacy Pharmaceuticals raises $9.3 million in Series B funding

Regenacy Pharmaceuticals is a clinical stage biopharmaceutical developer. Regenacy Pharmaceuticals is developing a new approach to the treatment of peripheral nerve disease, which is not limited to pain and symptom management, but also restores peripheral nerve function, treats diabetic peripheral neuropathy (DPN) and other patients with chronic diseases. Recently announced a $9.3 million Series B financing led by Cobro Ventures, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA VENTURE HOLDINGS LIMITED and other undisclosed private investors. Regenacy plans to use the Series B financing to continue advancing its ricolinostat clinical development program.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment